Innovation
Pushing the boundaries of antibody-based therapeutics through novel multispecifics and optimized drug conjugates
Our fully integrated R&D engine is powered by our proprietary platforms and driven by our team of world-class researchers who have a proven ability to discover, develop, and collaborate with partners to commercialize our novel agents globally.
Our pipeline of novel multifunctional therapeutics is supported by our clinically validated, best-in-class multispecific antibody therapeutics (MSATs) and antibody–drug conjugates (ADCs) technology platforms.
Multispecific antibody therapeutics enable engagement of independent targets expressed on the same cell or on different cell populations, engaging biology and affording therapeutic opportunities, not feasible with single-target antibodies or antibody combinations. Our clinically validated technologies harness the flexibility of our proprietary Azymetric™ technology as a foundation to solve biological challenges.
ADC technology harnesses the power of potent payloads and the specificity of antibodies to selectively deliver small molecule drugs to tumors. We are applying our proprietary ADC payloads and other drug conjugate technologies in the development of novel therapeutic candidates. These technologies can also be paired with our Azymetric™ technology platform to create next-generation bispecific ADCs.
Pipeline
Our clinical and preclinical pipeline includes wholly owned and partnered therapeutic candidates targeting difficult-to-treat cancers and other serious diseases.
